Alterity Therapeutics Limited (PBN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Alterity Therapeutics Limited (PBN) has a cash flow conversion efficiency ratio of -0.222x as of June 2023. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-5.06 Million ≈ $-5.91 Million USD) by net assets (€22.81 Million ≈ $26.67 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See debt-free asset ratio of Alterity Therapeutics Limited to measure how much of total assets are equity-financed.
Alterity Therapeutics Limited - Cash Flow Conversion Efficiency Trend (2014–2025)
This chart illustrates how Alterity Therapeutics Limited's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore PBN strategic capital deployment ratio to see how much of total assets are deployed in long-term investments.
Alterity Therapeutics Limited Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Alterity Therapeutics Limited ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Mandom Indonesia Tbk
JK:TCID
|
0.032x |
|
Aksu Enerji ve Ticaret AS
IS:AKSUE
|
0.002x |
|
DaChan Food (Asia) Limited
F:3DS
|
N/A |
|
MediciNova Inc
NASDAQ:MNOV
|
-0.039x |
|
Futebol Clube do Porto - Futebol S.A.D.
LS:FCP
|
-0.035x |
|
Cufe Ltd
AU:CUF
|
-0.110x |
|
Harboes Bryggeri A/S
CO:HARB-B
|
0.029x |
|
HLB Life Science Co. Ltd
KQ:067630
|
-0.016x |
Annual Cash Flow Conversion Efficiency for Alterity Therapeutics Limited (2014–2025)
The table below shows the annual cash flow conversion efficiency of Alterity Therapeutics Limited from 2014 to 2025. For the full company profile with market capitalisation and key ratios, see PBN market cap.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-06-30 | €42.40 Million ≈ $49.57 Million |
€-11.45 Million ≈ $-13.39 Million |
-0.270x | +70.44% |
| 2024-06-30 | €13.80 Million ≈ $16.13 Million |
€-12.61 Million ≈ $-14.74 Million |
-0.914x | -4.02% |
| 2023-06-30 | €22.81 Million ≈ $26.67 Million |
€-20.04 Million ≈ $-23.42 Million |
-0.878x | -152.49% |
| 2022-06-30 | €35.47 Million ≈ $41.47 Million |
€-12.34 Million ≈ $-14.42 Million |
-0.348x | +38.84% |
| 2021-06-30 | €30.47 Million ≈ $35.62 Million |
€-17.33 Million ≈ $-20.26 Million |
-0.569x | +56.88% |
| 2020-06-30 | €7.15 Million ≈ $8.36 Million |
€-9.43 Million ≈ $-11.03 Million |
-1.319x | -56.46% |
| 2019-06-30 | €16.55 Million ≈ $19.35 Million |
€-13.95 Million ≈ $-16.31 Million |
-0.843x | -117.06% |
| 2018-06-30 | €16.08 Million ≈ $18.80 Million |
€-6.25 Million ≈ $-7.30 Million |
-0.388x | -56.86% |
| 2017-06-30 | €23.69 Million ≈ $27.70 Million |
€-5.87 Million ≈ $-6.86 Million |
-0.248x | -4.68% |
| 2016-06-30 | €31.37 Million ≈ $36.67 Million |
€-7.42 Million ≈ $-8.67 Million |
-0.237x | +14.91% |
| 2015-06-30 | €39.11 Million ≈ $45.73 Million |
€-10.87 Million ≈ $-12.71 Million |
-0.278x | +22.62% |
| 2014-06-30 | €37.69 Million ≈ $44.06 Million |
€-13.54 Million ≈ $-15.83 Million |
-0.359x | -- |
About Alterity Therapeutics Limited
Alterity Therapeutics Limited is engages in research and development of Parkinsonian and neurodegenerative disorders, including Multiple System Atrophy (MSA) and Parkinson's disease. The company's lead drug candidate is ATH434, a small molecule drug candidate that has completed Phase II clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II… Read more